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Background: Tick-borne encephalitis (TBE) is a poten-
tially severe neurological disease caused by TBE virus 
(TBEV). In Europe and Asia, TBEV infection has become 
a growing public health concern and requires fast and 
specific detection. Aim: In this observational study, 
we evaluated a rapid TBE IgM test, ReaScan TBE, for 
usage in a clinical laboratory setting. Methods: Patient 
sera found negative or positive for TBEV by serological 
and/or molecular methods in diagnostic laboratories 
of five European countries endemic for TBEV (Estonia, 
Finland, Slovenia, the Netherlands and Sweden) were 
used to assess the sensitivity and specificity of the 
test. The patients’ diagnoses were based on other 
commercial or quality assured in-house assays, i.e. 
each laboratory’s conventional routine methods. For 
specificity analysis, serum samples from patients 
with infections known to cause problems in serology 
were employed. These samples tested positive for e.g. 
Epstein–Barr virus, cytomegalovirus and  Anaplasma 
phagocytophilum, or for flaviviruses other than 
TBEV, i.e. dengue, Japanese encephalitis, West Nile 
and Zika viruses. Samples from individuals vacci-
nated against flaviviruses other than TBEV were also 
included. Altogether, 172 serum samples from patients 
with acute TBE and 306 TBE IgM negative samples 
were analysed. Results: Compared with each labora-
tory’s conventional methods, the tested assay had 
similar sensitivity and specificity (99.4% and 97.7%, 
respectively). Samples containing potentially inter-
fering antibodies did not cause specificity problems.
Conclusion: Regarding diagnosis of acute TBEV infec-
tions, ReaScan TBE offers rapid and convenient com-
plementary IgM detection. If used as a stand-alone, it 
can provide preliminary results in a laboratory or point 
of care setting.
Introduction
Tick-borne encephalitis virus (TBEV) is the most 
important tick-transmitted virus causing human dis-
ease in Europe and Asia [1–4]. TBEV belongs to the 
genus Flavivirus, within the Flaviviridae family, and can 
be divided into three distinct subtypes: the European 
(TBEV-Eur, formerly known as Central European 
encephalitis virus), the Siberian (TBEV-Sib, formerly 
known as Siberian encephalitis virus), and the Far 
Eastern (TBEV-FE, formerly known as Russian Spring 
Summer encephalitis virus) subtypes [3]. Recently, 
two new subtypes of TBEV (Himalayan and Baikalian) 
have been characterised [5,6]. Several studies suggest 
that the case fatality rate for TBE caused by TBEV-Eur 
is 0–4% [1,7] by TBEV-Sib 2-3% [1,7] and by TBEV-FE 
6–40% [1,3,7,8]. However, according to Ruzek et al., 
2019 [9] the overall TBE mortality rate in Russia is 
approximately 2% (i.e. TBEV-Sib and TBEV-FE infec-
tions). Thus, data on fatality rates of TBEV are not com-
prehensive since, aside from the infecting subtype, 
other factors (such as healthcare system efficiency, 
population genetics or living conditions) may come 
into play. TBEV is maintained in ticks and in their wild 
vertebrate hosts in forested natural foci [10]. The main 
reservoir hosts are found among small mammals (e.g. 
rodents, insectivores), while larger animals (e.g. deer), 
despite being important feeding hosts for ticks, do not 
seem to play any considerable role in the maintenance 
of the virus within its foci [2,11].
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Table 1a
Serological and molecular assays used for comparison and evaluation of ReaScan TBEa in five European countries
Virus and method Comment Method
Finland
TBEV serology Presence of serum or CSF IgM antibodies
Microcapture IgM EIA based on recombinant TBEV antigen produced in 
insect cells infected with recombinant baculovirus expressing TBEV prM 
and E proteins [24]
Estonia
TBEV serology Presence of serum IgM antibodies IMMUNOZYM FSME (TBE) IgM (Progen, Heidelberg, Germany)
Slovenia
TBEV serology Presence of serum and CSF IgM and IgG antibodies
Enzygnost Anti-TBE virus ELISA IgM, IgG test (Siemens GmbH, Marburg, 
Germany) in accordance with the manufacturer‘s instructions
TBEV PCR Presence of RNA in serum and CSF samples
QIAamp Viral RNA Mini Kit (QIAGEN, Hilden, Germany) according to the 
manufacturer’s instructions 
 
TaqMan Fast Virus 1-Step Master Mix (Applied Biosystems, Carlsbad, 
California, United States) was used for quantitative reverse transcription 
PCR (RT-PCR) performed as reported by Schwaiger and co-workers [40]
CMV and EBV serology Presence of serum IgM and IgG antibodies
DiaSorin LIAISONXL CLIA (DiaSorin SpA, Saluggia, Italy) in accordance 
with the manufacturer‘s instructions
DENV serology Presence of serum IgM and IgG antibodies
Mosaic: Dengue Virus Types 1–4 IIFT IgG and IgM test (EUROIMMUN 
Medizinische Labordiagnostika AG, Lübeck, Germany) in accordance with 
the manufacturer‘s instructions
Anaplasma 
phagocytophilum serology
Presence of IgM and IgG 
antibodies in acute and 
convalescent serum
IFA for the presence of specific IgG antibodies to A. 
phagocytophilum antigens prepared from a human promyelocytic cell line 
(HL60) infected with a human isolate of A. phagocytophilum [41]
Sweden
TBEV serology Presence of serum IgM and IgG antibodies
Enzygnost Anti-TBE virus ELISA IgM, IgG test (Siemens GmbH, Marburg, 
Germany) in accordance with the manufacturer‘s instructions
HSV and VZV serology Presence of serum IgM and IgG antibodies
Enzygnost Anti-HSV Virus ELISA IgM, IgG test; Enzygnost Anti-VZV Virus 
IgM, IgG test (SiemensGmbH, Marburg, Germany) in accordance with the 
manufacturer‘s instructions
CMV and EBV serology Presence of serum IgM and IgG antibodies
Abbott Architect CMIA CMV IgM and IgG; Abbott Architect CMIA EBV IgM 
and IgG (VCA and EBNA) (Abbott Laboratories, Chicago, Illinois, United 
States) in accordance with the manufacturer‘s instructions
YFV serology Presence of serum IgG antibodies
In house indirect IFA IgG; (antigen prepared from YFV Asibi vaccine strain 
on Vero cells) and neutralisation assay (YFV Asibi strain and BHK21 cells) 
performed as reported by Vene et al. [42,43]
WNV serology Presence of serum IgM and IgG antibodies
In house indirect IFA IgG (antigen prepared from WNV 304 strain on Vero 
cells) [42]; Pan Bio WNV IgM (PANBIO, Inc., Columbia, Maryland, United 
States) in accordance with the manufacturer‘s instructions
JEV serology Presence of serum IgM and IgG antibodies
In house indirect IFA IgM and IgG (antigen prepared from JEV Nakayama 
strain on Vero cells) and neutralisation assay (JEV Nakayama strain and 
BHK21 cells) performed as reported by Vene et al. [42,43]
DENV serology Presence of serum IgM and IgG antibodies
In house indirect IFA IgG (antigen prepared from DENV2 NGC strain on 
Vero cells) performed as described by Vene et al. [42] 
 
Pan Bio DENV IgM (PANBIO, Inc., Columbia, Maryland, United States) in 
accordance with the manufacturer‘s instructions
the Netherlands
TBEV serology Presence of serum IgM and IgG antibodies
SERION ELISA classic FSME Virus/TBE Virus IgG and IgM (Serion 
Diagnostics, Wurzburg, Germany) in accordance with the manufacturer’s 
instructions. 
 
Neutralisation assay as described by Reusken et al. [27]
ZIKV serology Presence of serum IgM and IgG antibodies
Euroimmun Zika ELISA IgM, IgG (Euroimmun AG, Lübeck, Germany) in 
accordance with the manufacturer’s instructions 
 
Neutralisation assay: virus neutralisation test ZIKV: as described by van 
der Eijk et al. [44]
CHIK: chikungunya; CHIKV: chikungunya virus; CMIA: chemiluminescence microparticle immunoassay; CMV: cytomegalovirus; CSF: 
cerebrospinal fluid; DENV: dengue virus; EA: early antigen; EBV: Epstein–Barr virus; EBNA: EBV nuclear antigen; EIA: enzyme immunoassay; 
FSME: Frühsommer-Meningoenzephalitis (same as TBE); HSV: herpes simplex virus; IFA: immunofluorescent assay; IIFT: indirect 
immunofluorescence test; JEV: Japanese encephalitis virus; NGC: New Guinea C ; TBE: tick-borne encephalitis (same as FSME); TBEV: tick-
borne encephalitis virus; VZV: varicella zoster virus; VCA: viral capsid antigen; WNV: West Nile virus; YFV: yellow fever virus; ZIKV: zika virus.
a ReaScan TBE IgM rapid test (Reagena, Toivala, Finland).
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The epidemiology of tick-borne encephalitis (TBE) is 
closely associated with the geographical distribution 
and ecology of tick vector species, and the periods of 
their feeding activity. Human infections usually occur 
as results of tick bites, but can also in rare occasions 
be acquired via consumption of unpasteurised milk 
and milk products from infected animals [2,12,13].
After a bite by an infected tick, a proportion of indi-
viduals will remain asymptomatic but 2–30% will 
develop an initial non-specific febrile illness lasting 
a few days, followed by an asymptomatic interval of 
1–2 weeks [3,14]. Approximately 30% of the patients 
who initially showed clinical symptoms will further 
develop neurological symptoms (mild meningitis to 
severe encephalitis) during a second phase of the dis-
ease [14,15]. According to a 10-year follow-up survey in 
Germany, 80% of patients with primary myelitic mani-
festations suffered long-term sequelae [16]. A recent 
study on post-encephalitic syndrome (PES) after TBE 
in Slovenia revealed that the frequency and severity 
of PES diminished over time following acute illness 
[17]. After 12 months, PES frequency stabilised while 
severity continued to decline. Unfavourable outcomes 
at 12 months and at the final hospital visit (at 7 years 
post-acute illness) were strongly associated with the 
presence of PES at previous time points [17].
The clinical symptoms of TBE are unspecific and the 
diagnosis has to be verified in the laboratory. The cri-
teria for confirmed TBE include central nervous sys-
tem (CNS) inflammation symptoms (e.g. meningitis, 
meningo-encephalitis, encephalomyelitis, encephalo-
radiculitis) and at least one of the laboratory criteria, 
which are either detection of the virus or its nucleic 
acid in a clinical specimen or detection of specific IgM 
and IgG antibodies in serum, seroconversion, or spe-
cific IgM in cerebrospinal fluid (CSF) [18].
The laboratory diagnosis of TBE is usually straight-
forward; in almost all cases, TBEV-specific IgM and 
usually also TBEV-IgG antibodies are present in the 
first serum samples drawn when the CNS symptoms 
have manifested (i.e. during the second phase of the 
disease). Intrathecal IgM and IgG responses can be 
detectable in CSF several days after their appearance 
in serum and previous studies found these in all cases 
at Day 10 after onset of CNS symptoms in [19,20].
TBEV can be isolated, or detected by real-time (RT)-
PCR, from blood during the first phase of the illness. 
The period of possible isolation and detection can be 
prolonged in patients with progressive disease and in 
immunocompromised patients [1,21-23].
Enzyme immunoassays (EIA, ELISA), based either on 
purified virions, recombinant proteins, or recombinant 
virus-like particles obtained by expression of prM and 
E proteins, are usually used for specific serodiagno-
sis [1,24]. Haemagglutination inhibition (HI) has also 
been widely used but it measures all different antibody 
classes and thereby requires a significant rise in anti-
body titre for a clear-cut diagnosis.
High cross-reactivity of the antigenic sites among the 
various pathogenic flaviviruses may cause TBE diag-
nostic problems when other flavivirus(es) co-circulate 
(e.g. West Nile virus (WNV) in southern and central 
Virus and method Comment Method
DENV serology Presence of serum IgM and IgG antibodies
Euroimmun DENV ELISA IgM, IgG (Euroimmun AG, Lübeck, Germany) 
in accordance with the manufacturer‘s instructions; Dengue Virus NS1 
(types 1–4) ELISA (Euroimmun AG, Luebeck, Germany) and Platelia 
Dengue NS1 Ag-ELISA (Biorad, Marnes-la-Coquette France) in accordance 
with the manufacturers‘ instructions
CHIKV serology Presence of serum IgM and IgG antibodies
Euroimmun IFA CHIK IgM and IgG (Euroimmun AG Lübeck, Germany) 
 
Neutralisation assay: virus neutralisation test CHIKV, in-house developed 
micro-neutralisation assay as described by van den Doel et al. [45]
JEV serology Presence of serum IgM and IgG antibodies Euroimmun IFA JEV IgM and IgG (Euroimmun AG, Lübeck, Germany)
CMV serology Presence of serum IgM and IgG antibodies
DiaSorin LIAISONXL CLIA CMV IgM and IgG, Avidity (DiaSorin SpA, 
Saluggia, Italy) in accordance with the manufacturer‘s instructions
EBV serology Presence of serum IgM and IgG antibodies
DiaSorin LIAISONXL CLIA EBV VCA IgG, EA IgG, EBNA IgG, VCA IgM 
(DiaSorin SpA, Saluggia, Italy) in accordance with the manufacturer‘s 
instructions
EBV PCR Presence of viral DNA In-house real-time quantitative PCR EBV as described by Niesters et al. [46]
CHIK: chikungunya; CHIKV: chikungunya virus; CMIA: chemiluminescence microparticle immunoassay; CMV: cytomegalovirus; CSF: 
cerebrospinal fluid; DENV: dengue virus; EA: early antigen; EBV: Epstein–Barr virus; EBNA: EBV nuclear antigen; EIA: enzyme immunoassay; 
FSME: Frühsommer-Meningoenzephalitis (same as TBE); HSV: herpes simplex virus; IFA: immunofluorescent assay; IIFT: indirect 
immunofluorescence test; JEV: Japanese encephalitis virus; NGC: New Guinea C ; TBE: tick-borne encephalitis (same as FSME); TBEV: tick-
borne encephalitis virus; VZV: varicella zoster virus; VCA: viral capsid antigen; WNV: West Nile virus; YFV: yellow fever virus; ZIKV: zika virus.
a ReaScan TBE IgM rapid test (Reagena, Toivala, Finland).
Table 1b
Serological and molecular assays used for comparison and evaluation of ReaScan TBEa in five European countries
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Europe, Usutu virus (USUV) in large parts of Europe) 
[25], or when travellers return from e.g. Japanese 
encephalitis virus (JEV), dengue virus (DENV) or Zika 
virus (ZIKV) endemic areas. In addition, TBEV-, JEV-, or 
yellow fever virus (YFV)-vaccinations may cause sub-
stantial diagnostic problems. In such cases, detection 
of TBEV-specific antibodies in CSF and neutralisation 
assays on convalescent serum samples are needed for 
a reliable TBE diagnosis. The neutralisation test, how-
ever, requires labour-intensive Biosafety Level 3 work 
– as well as a large panel of flaviviruses to be compre-
hensive. The IgM responses to the various flaviviruses 
are generally more virus-specific and reliable markers 
of acute infection. In cases of suspected TBEV infection 
despite TBEV vaccination, second samples showing a 
delayed rise in antibody titre, a late TBEV-positive IgM, 
or the detection of a TBEV-specific CSF response, are 
required for the diagnosis [26].
In the present study, we evaluated the performance of 
a new commercially available rapid test called ReaScan 
TBE IgM rapid test, Reagena Oy Ltd, Toivala, Finland, 
for the timely diagnosis of acute TBE by detection of 
TBEV-specific IgM antibodies.
Methods
Samples
All samples were stored at −20 °C before analysis by 
Reascan TBE IgM. All TBE IgM positive samples used 
correspond to TBE-confirmed cases in accordance with 
the European Union (EU) case definition criteria [18].
HUSLAB, Helsinki, Finland
Serum samples from Finnish patients having prior 
tested positive (n = 55) and negative (n = 100) for TBE 
IgM by HUSLAB EIA as described below were analysed 
at HUSLAB in Helsinki, Finland.
National Institute for Health Development, Tallinn, 
Estonia
Estonian patients’ serum samples (n = 47), which were 
previously found positive for TBE IgM by IMMUNOZYM 
FSME (TBE) IgM (Progen, Heidelberg, Germany) as 
described below were analysed at the Laboratory of 
Clinical Microbiology in Uppsala, Sweden.
Institute of Microbiology and Immunology, 
Ljubljana, Slovenia
Serum samples from Slovenian patients, which previ-
ously tested TBE IgM positive (n = 8) and TBE IgM nega-
tive (n = 31) by Enzygnost Anti-TBE virus ELISA IgM test 
(Siemens GmbH, Marburg, Germany) were analysed 
Figure 
ReaScan TBEa IgM results on samples from TBE patients and negative controls (n = 522 samples)
0
100
200
300
400
500
600
Re
aS
ca
n 
re
ad
er
 v
al
ue
 (A
U)
A. Results-Estonia and Sweden (n = 204) 
TBE V+ TBEV - HSVEBVCMV VZV
JEV, 
WNV, 
YFV
DENV
0
100
200
300
400
500
600
0Re
aS
ca
n 
re
ad
er
 v
al
ue
 (A
U)
B. Results-Finland (n = 155) 
TBEV-TBEV+
0
100
200
300
400
500
600
Re
aS
ca
n 
re
ad
er
 v
al
ue
s (
AU
) C. Results-Slovenia (n = 83) 
TBEV 
PCR+
EBV/CMV DENV VBTTBEV+ TBEV- A. Phag
Positive ReaScan TBE IgM rapid results
Negative ReaScan TBE IgM test results
Equivocal ReaScan TBE IgM rapid test results
TBEV+ CMV EBV DENV CHIKV JEV YFV ZIKV
0
100
200
300
400
500
600
Re
aS
ca
n 
re
ad
er
 v
al
ue
 (A
U)
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A.phag: Anaplasma phagocytophilum; AU: arbitrary units; CHIKV: Chikungunya virus; CMV: cytomegalovirus; DENV: dengue virus; EBV: 
Epstein–Barr virus; JEV: Japanese encephalitis virus infection; TBE: tick-borne encephalitis; TBEV: tick-borne encephalitis virus; TBEV+: 
Tick-borne encephalitis virus positive using another method than ReaScan TBE, TBEV-: Tick-borne encephalitis virus negative using another 
method than ReaScan TBE; VBT: vaccine breakthrough; WNV: West Nile virus; YFV: yellow fever virus vaccination; ZIKV: zika virus.
a ReaScan TBE IgM rapid test (Reagena, Toivala, Finland).
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at the Institute for Microbiology and Immunology in 
Ljubljana, Slovenia. The 31 IgM negative samples 
included some, which were positive for Epstein–Barr 
virus (EBV) (n = 2), EBV/cytomegalovirus (CMV) (n = 4), 
DENV (n = 4) and Anaplasma phagocytophilum (n = 10).
In addition, 18 serum samples and one CSF sample 
from seven selected TBE patients previously confirmed 
positive by TBEV PCR, and 26 serum samples and 12 
CSF samples from 11 TBE vaccine failure patients [26] 
were analysed.
Laboratory of Clinical Microbiology, Uppsala, Sweden
Swedish patients’ serum samples, which had tested 
TBE IgM positive (n = 50) and TBE IgM negative (n = 30) 
by Enzygnost Anti-TBE virus ELISA IgM, IgG test as 
described below were analysed at the Laboratory of 
Clinical Microbiology in Uppsala, Sweden. In addition, 
50 acute phase serum samples from 20 EBV, 10 CMV, 
10 herpes simplex virus (HSV) and 10 varicella zos-
ter virus (VZV) infected patients, were analysed. All 
of these 50 samples had tested IgM TBE negative by 
Enzygnost Anti-TBE virus ELISA IgM test.
Furthermore, 26 acute phase sera from Swedish 
patients with other flavivirus infections (22 DENV, 2 JEV, 
2 WNV) and one serum sample from a YFV-vaccinated 
individual were analysed. These 27 samples were from 
individuals with no medical reason to check for TBEV 
infection so they were not tested for TBE IgM prior to 
the analysis by ReaScan TBE in this study.
Viroscience laboratory, Erasmus MC, Rotterdam, the 
Netherlands
Serum samples (n = 12) from confirmed TBE patients 
(based on clinical symptoms, SERION ELISA clas-
sic FSME Virus/TBE Virus IgM (Serion Diagnostics, 
Wurzburg, Germany) and virus neutralisation test) [27], 
which were TBE IgM positive, as well as 68 control 
potentially cross-reactive serum samples confirmed 
negative by virus neutralisation test were analysed. 
The 68 control samples were positive for chikungunya 
virus (CHIKV; n = 10), CMV (n = 8), DENV (n = 16), EBV 
(n = 9), JEV (n = 1), ZIKV (n = 10), or from JEV vaccinated 
(n = 4) or YFV vaccinated patients (n = 10).
Serological assays
ReaScan TBE IgM rapid test
The ReaScan TBE IgM rapid test is a novel qualitative 
immunochromatographic lateral flow assay for the 
diagnosis of acute TBEV infection. Anti-human IgM 
captures IgM of the sample onto the test line. TBEV-
specific IgM is detected by recombinant TBE virus anti-
gen-colloidal gold complex. The intensity of the test 
line is proportional to the amount of TBE virus IgM in 
the sample and is converted into numerical value by 
the dedicated test reader. The assay was performed 
according to the kit instructions. Briefly, serum sam-
ples were diluted with dilution buffer (1:400) and 
100 µL of sample dilution was pipetted into the conju-
gate vial. Then, 80 µL of sample-conjugate mixture was 
transferred into the test cassette’s sample well. After 
20 min, the intensity of the test line was read with the 
test reader and the result was interpreted as negative, 
equivocal or positive according to the lot-specific cut-
off values. One to two replicas were made in the five 
different laboratories.
HUSLAB tick-borne encephalitis IgM enzyme 
immunoassay
The TBEV-IgM test used at HUSLAB, Helsinki, Finland 
is a microcapture IgM EIA based on recombinant 
Table 2
ReaScan TBEa overall performance on serum samples prior found tick-borne encephalitis virus IgM positive or 
negativeb (n = 313 samples)
Result description
Country 
 
(ReaScan TBEa IgM kit lot used)
Total
Estonia 
 
(QE27/1)
Finland 
 
(RA12/1)
Slovenia 
 
(QE27/1 and QB27/1)
Sweden 
 
(QE27/1)
The Netherlands 
 
(SH16/1)
TBEV IgM negativec 0 100 11 30 0 141
ReaScan negative 0 97 11 30 0 138
ReaScan equivocal 0 2 0 0 0 2
ReaScan positive 0 1 0 0 0 1
TBEV IgM positived 47 55 8 50 12 172
ReaScan negative 0 0 0 0 0 0
ReaScan equivocal 1 0 0 0 0 1
ReaScan positive 46 55 8 50 12 171
TBEV: tick-borne encephalitis virus.
a ReaScan TBE IgM rapid test (Reagena, Toivala, Finland).
b In this table the TBEV IgM negative samples were not from patients known to have vaccinations, or infections other than with TBEV, that 
might cause diagnostic problems such as serological cross-reactions.
c In this row, samples which tested TBEV IgM negative through another method than ReaScan TBE are shown.
d In this row, samples which tested TBEV IgM positive through another method than ReaScan TBE are shown.
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TBEV antigen produced in insect cells infected with 
recombinant baculovirus expressing TBEV prM and E 
proteins [24]. Briefly, the diluted serum (or CSF) sam-
ples were incubated on goat anti-human IgM (Cappel/
MP Biomedicals, Santa Ana, California, United States 
(US)) coated EIA strips for 30 min at 37 °C. Unbound 
excess antibody was washed by phosphate-buffered 
saline (PBS) with 0.05% TWEEN-20. The recombinant 
antigen (diluted recombinant baculovirus-infected 
insect cell supernatant) was incubated with the strip 
for 45 min 37 °C and washed as above. A mouse mon-
oclonal anti-TBEV-E protein antibody 1786 [28] was 
incubated and washed as above, after which a per-
oxidase-conjugated donkey anti-mouse IgG antibody 
(Jackson Immunoresearch, West Grove, Pennsylvania, 
US) was added, incubated and washed. The enzyme 
reaction was detected by TMB substrate (Sigma, 
Rockford, Illinois, US) and the reaction stopped by 
0.5 M H2SO4. The absorbance was measured at 450 nm 
and the absorbance values adjusted as described in 
Jääskeläinen et al. 2003 [24].
Commercially available tick-borne encephalitis IgM 
enzyme immunoassays
The Enzygnost Anti-TBE virus ELISA IgM, IgG test was 
used according to the manufacturer’s instruction in the 
Slovenian and Swedish laboratories. The IMMUNOZYM 
FSME (TBE) IgM was used according to the manufac-
turer’s instructions in the Estonian laboratory. The 
SERION ELISA classic FSME Virus/TBE Virus IgG and 
IgM was used according to manufacturer’s instructions 
in the Dutch laboratory.
Other serological and molecular assays
Assays used by the different laboratories for diagnosis 
of other infections than TBEV are listed in  Table 1  as 
well as any serological or molecular assays for TBE 
diagnosis.
Ethical statements
Specific ethical approvals were at the time of the study 
considered not needed for Sweden, Estonia or Finland 
for anonymous/within hospital laboratory pseudo-
nyms. For Slovenia, this study was performed as a part 
of the ongoing study on tick-transmitted infections 
at the Institute of Microbiology and Immunology, 
Ljubljana, and ethical clearance was obtained accord-
ing to national legislation (NMEC number 131/06/13). 
For the Netherlands: ethical approval was obtained 
from the Erasmus MC Medical Ethical Committee (MEC-
2015–306) to anonymously analyse the used samples 
of all patients.
Results
The results from the evaluation by the five diagnostic 
reference laboratories are shown in Figure A–D.
Assay sensitivity
Based on a locally available total of 172 serum sam-
ples from earlier diagnosed TBE patients, the sensi-
tivity was calculated to be 99.4%, i.e. all except one 
serum sample were found positive by the assay (Table 
2 and Table 3).
Assay specificity
Based on 141 locally-available samples prior testing 
TBEV IgM negative using the routine method for each 
laboratory (i.e. other commercial TBE assays than 
ReaScan TBE or quality assured in-house methods) in 
Finland, Slovenia and Sweden, a specificity of 97.9% 
(138/141) was found (Table 2 and Table 3).
To further analyse the specificity, 73 patient serum sam-
ples from CMV, EBV, HSV and VZV infected patients and 
10 serum samples from  A. phagocytophilum  infected 
individuals were tested. Based on those 83 potentially 
interfering samples, a specificity of 96.4% (80/83) was 
found (Table 4 and Table 5).
Other flavivirus/togavirus infections
The flaviviruses are known to share a number of com-
mon antigenic sites causing serological cross-reactions 
and thereby problems in serological diagnostics. To 
evaluate the level of potential cross-reactivity of the 
assay to other flavivirus infections, a total of 57 serum 
samples from DENV, JEV, WNV, and ZIKV infected 
individuals were analysed. In addition, 15 sera from 
JEV- and YFV-vaccinated individuals and 10 sera from 
individuals infected with CHIKV (a togavirus) were ana-
lysed. Of these 82 sera 81 showed a negative result 
Table 3
Sensitivity and specificity of the ReaScan TBE IgM rapid testa (n = 313 samples)
Type of patients
ReaScana result
Total
Sensitivityb 
 
(95% CI)
Specificityc 
 
(95% CI)TBE positive TBE equivocal TBE negative
TBE patients 171 1 0 172 99.4% 
 
(96.8–100%)
97.9% 
 
(93.9–99.6%)Non-TBE patients 1 2 138 141
CI: confidence interval; TBE: tick-borne encephalitis.
a ReaScan TBE IgM rapid test (Reagena, Toivala, Finland).
b Equivocal results calculated as false negative.
c Equivocal results calculated as false positive.
In this table, samples were not from patients known to have vaccinations, or infections other than with TBE virus, that might cause diagnostic 
problems such as serological cross-reactions.
7www.eurosurveillance.org
and one sample (from an YFV-vaccinated individual) 
was positive (Table 4), giving a specificity of 98.8% 
(Table 5).
The assay showed an overall specificity of 97.7% 
((138 + 80 + 81)/(141 + 83 + 82) = 0.977) based on all the 
306 above-mentioned TBEV IgM negative samples.
ReaScan TBE compared to Enzygnost IgM 
ELISA
Thirty-one TBEV IgM negative patient serum samples 
from Slovenia, 18 of which were previously tested as 
false TBEV IgM positive by Enzygnost Anti-TBE virus 
ELISA, were analysed by the ReaScan TBE. These 18 
false TBEV IgM positive samples, initially tested by 
the Siemens Enzygnost IgM assay were samples from 
patients whose consecutive second (one week later) 
and third serum (two weeks later) samples were avail-
able. In all consecutive serum samples they did not 
present any specific IgG against TBEV, i.e. no IgG sero-
conversion within a three-week time period. Besides, 
their CSF samples were IgM and IgG negative. Based on 
these data, these TBEV IgM positive samples were con-
sidered as false positive. One of the samples showed 
equivocal result by the ReaScan IgM, all other 17 sam-
ples showed a negative result (Table 6).
Of 18 samples from seven Slovenian PCR-confirmed 
TBE patients, 11 and 10 tested positive by the ReaScan 
TBE and Enzygnost, respectively (Table 6). A total of 
26 serum samples from vaccine failure TBE patients 
showed similar results with both methods (Table 6).
Discussion
TBE is an important and growing public health problem 
in Europe and Asia [1–4]. In 2016, France reported a 
marked increase of TBE cases, following which Sweden 
reported its highest numbers of TBE cases since 1956 
when comparable records were first kept, with 391 and 
385 cases during 2017 and 2018, respectively, while in 
Finland the number of TBE cases has more than dou-
bled during the last decade, fatalities have occurred 
and the disease has spread to new areas [29–32]. 
The Netherlands, previously TBE-free, has reported 
its emergence from 2016 [33], and in Denmark, TBE 
was reported in a new geographical hot spot (Tisvilde 
Hegn, in Northern Zealand) [34]. Furthermore, TBEV 
was recently detected for the first time in ticks in the 
United Kingdom (2019) [35]. The cause of the increase 
in TBE case numbers despite an increase in the fre-
quency of TBE vaccinations [36] in several European 
countries is not yet fully understood, but climate 
change (increased temperature and humidity) may be 
Table 4
ReaScan TBEa performance on serum samples containing potentially cross-reactive or problematic serab (n = 209 samples)
Patient/sample characteristic
Number of serum samples in each country Total 
 
n = 209
Negative
ReaScan TBE results
Slovenia Sweden The Netherlands Equivocal Positive
Acute infections/problematic sera
Epstein–Barr virus 2c 20c 9d 31
83
30 1 0
Cytomegalovirus 4c 10c 8d 22 20 2 0
Herpes simplex virus 0 10c 0 10 10 0 0
Varicella zoster virus 0 10c 0 10 10 0 0
Anaplasma phagocytophilum 10c 0 0 10 10 0 0
Other flavivirus and chikungunya virus infection or vaccination
Dengue virus 4c 22e 16d 42
82
42 0 0
Japanese encephalitis virus 0 2e 1d 3 3 0 0
Japanese encephalitis vaccinated 0 0 4d 4 4 0 0
West Nile virus 0 2e 0 2 2 0 0
Yellow fever vaccinated 0 1e 10d 11 10 0 1
Zika virus 0 0 10d 10 10 0 0
Chikungunya virus 0 0 10d 10 10 0 0
TBE virus and TBE vaccination breakthrough
TBE PCR positive 18f 0 0 18
44
7 0 11
TBE vaccination breakthrough 26g 0 0 26 4 3 19
TBE: tick-borne encephalitis.
a ReaScan TBE IgM rapid test (Reagena, Toivala, Finland).
b In the table samples were from patients with infections other than TBE virus that might cause diagnostic problems by serological cross-
reactions, as well as from patients testing positive for TBE virus nucleic acid material, or from patients vaccinated against a flavivirus.
c Tested TBE IgM negative by Enzygnost Anti-TBE virus ELISA test (Siemens GmbH, Marburg, Germany).
d Tested negative by TBE virus neutralisation test.
e Not tested for TBE by another method prior to analysis with ReaScan TBE.
f Of these 18 samples, eight had tested TBE IgM negative and 10 TBE IgM positive by Enzygnost Anti-TBE virus ELISA test (Siemens GmbH, 
Marburg, Germany).
g Of these 26 samples, five had tested TBE IgM negative and 21 TBE IgM positive by Enzygnost Anti-TBE virus ELISA test (Siemens GmbH, 
Marburg, Germany).
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one important factor. Other potential reasons can be 
increased awareness and testing.
Due to the very low amount, or in most cases complete 
absence, of detectable TBEV RNA at the onset of the 
CNS symptoms in immunocompetent patients, serol-
ogy is generally required for TBEV diagnostics. Routine 
laboratory diagnosis of acute TBE cases is therefore 
usually performed by immunoassays such as EIAs or 
ELISAs, designed for the detection of TBEV-specific 
IgM. The major potential problems in serological TBEV 
diagnostics, as also seen for the diagnosis of all other 
human-pathogenic flavivirus infections (e.g. DENV, 
YFV, JEV, ZIKV), are due to high level of cross-reactive 
epitopes among the flaviviruses: (i) cross-reactions by 
antibodies induced by infection by another flavivirus, 
(ii) cross-reactive antibodies induced by vaccination 
against another flavivirus, and (iii) less specific viral 
antigens used in the assay. Several commercial TBE IgM 
assays are available and some comparisons between 
these assays are available at present [27,37–39]. In 
this study, we compared the ReaScan TBE IgM rapid 
test with the conventional routine methods of several 
laboratories in a clinical laboratory setting. Our results 
revealed a high sensitivity (99.4%) when serum sam-
ples from 172 previously diagnosed TBE patients from 
five European countries were analysed. We also found 
a high specificity (97.9%) when 141 samples from pre-
viously diagnosed non-TBEV infections were analysed. 
Interestingly, there were no major differences in sen-
sitivity or specificity in the five laboratories that par-
ticipated in this study, despite the differences in the 
respective reference assays.
The specificity of the assay evaluated here was fur-
ther analysed by the use of well-known ‘serologically 
problematic’ samples (i.e. from patients with differ-
ent acute herpesvirus (CMV, EBV, HSV and VZV) or  A. 
phagocytophilum infections) and samples from patients 
infected by other flaviviruses (i.e. DENV, JEV and ZIKV) 
or vaccinated against YFV and JEV. The results revealed 
a mean specificity of 97.6% ((80 + 81)/(83 + 82) = 0.976) 
together for those two groups of potentially more com-
plicated samples.
The assay presented here is based on soluble recom-
binant TBE virus antigen expressed in insect cells. It 
is well known that recombinant antigens expressed by 
mammalian or insect cells usually result in higher spe-
cificities as compared with antigens expressed in bac-
terial systems [24]. Also, the assay format, where the 
measurement of the test line intensity is performed by a 
dedicated test reader (instead of visual interpretation), 
may improve both the sensitivity and the specificity of 
the assay and reduces the user-dependent errors. The 
fact that the IgM responses to the various flaviviruses 
are generally more virus-specific, as compared with the 
later IgG responses, is in line with the observed high 
specificity, also when analysing acute sera from e.g. 
DENV, JEV, YFV and ZIKV infected patients.
Our results thereby indicated that the recombinant anti-
gen used in the assay is antigenically sufficiently dif-
ferent from the corresponding antigens among DENV, 
JEV, YFV and ZIKV. This is likely due to the more distant 
relationship of the tick-borne flaviviruses (e.g. TBEV) 
to the mosquito-borne flaviviruses such as DENV, JEV, 
YFV and ZIKV.
In conclusion, our study revealed a similarly high sen-
sitivity and high specificity of the ReaScan TBE as 
compared with the assays used by the diagnostic labo-
ratories that participated in this study. Other advan-
tages of the assay are its rapid format (20 min), its 
suitability for analysing one sample at each time (i.e. 
no need to collect samples to have enough numbers 
Table 5
Specificity of the ReaScan TBE IgM rapid testa evaluated by potentially interfering serum samples and potentially cross-
reactive IgM resulting from other flavivirus infections (n = 165 samples)
Type of samples
ReaScana result
Total
Specificity 
 
(95% CI)
TBE 
positive
TBE 
equivocalb
TBE 
negative
Samples with potentially interfering agents 
 
(from patients with A. phagocytophilum, CMV, EBV, HSV and VZV 
infections)c
0 3 80 83
96.4% 
 
(89.8–99.3%)
Samples from patients with other flavivirus/togavirus (DENV, JEV, 
WNV, YFV, ZIKV, CHIKV) infections/vaccinationsd 1
e 0 81 82
98.8% 
 
(93.4–100%)
A. phagocytophilum: Anaplasma phagocytophilum; CHIKV: Chikungunya virus; CI: confidence interval; CMV: cytomegalovirus; DENV: dengue 
virus; EBV: Epstein–Barr virus; HSV: herpes simplex virus; JEV: Japanese encephalitis virus; TBE: tick-borne encephalitis; VZV: varicella 
zoster virus; WNV: West Nile virus; YFV: yellow fever virus; ZIKV: zika virus.
TBE: tick-borne encephalitis.
a ReaScan TBE IgM rapid test (Reagena, Toivala, Finland).
b The equivocal results were calculated as false positives.
c Among these 83 samples, 66 had tested TBE IgM negative by Enzygnost Anti-TBE virus ELISA test (Siemens GmbH, Marburg, Germany) and 17 
had tested negative by TBE virus neutralisation test.
d Among these 82 samples, four had tested TBE IgM negative by Enzygnost Anti-TBE virus ELISA test (Siemens GmbH, Marburg, Germany), 27 
were from individuals with no medical reason to check for TBEV infection and 51 had tested negative by TBE virus neutralisation test.
e This sample was from a YFV vaccinated individual.
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to perform an EIA test), and the possibility to use it as 
a Point-of-Care (POC) test to allow rapid diagnosis in 
primary care settings/outside central laboratories by 
non-specialised personnel.
However, to fulfil the EU case definition criteria, detec-
tion of TBEV IgM alone is not sufficient. Our results 
suggest that the assay is valuable as a convenient com-
plement for diagnosis of acute TBE infections, either as 
a complementary method for rapid IgM detection for 
laboratories that already have a TBE EIA/ELISA-method 
or as a stand-alone method for preliminary results in a 
laboratory or POC setting.
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